Original Article
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
N Engl J Med 2008; 358:2776-2786June 26, 2008
- Abstract
Background
We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.
Methods
In this randomized, double-blind trial, 2531 patients who were to undergo total knee arthroplasty received either oral rivaroxaban, 10 mg once daily, beginning 6 to 8 hours after surgery, or subcutaneous enoxaparin, 40 mg once daily, beginning 12 hours before surgery. The primary efficacy outcome was the composite of any deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 13 to 17 days after surgery. Secondary efficacy outcomes included major venous thromboembolism (i.e., proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death related to venous thromboembolism) and symptomatic venous thromboembolism. The primary safety outcome was major bleeding.
Results
The primary efficacy outcome occurred in 79 of 824 patients (9.6%) who received rivaroxaban and in 166 of 878 (18.9%) who received enoxaparin (absolute risk reduction, 9.2%; 95% confidence interval [CI], 5.9 to 12.4; P<0.001). Major venous thromboembolism occurred in 9 of 908 patients (1.0%) given rivaroxaban and 24 of 925 (2.6%) given enoxaparin (absolute risk reduction, 1.6%; 95% CI, 0.4 to 2.8; P=0.01). Symptomatic events occurred less frequently with rivaroxaban than with enoxaparin (P=0.005). Major bleeding occurred in 0.6% of patients in the rivaroxaban group and 0.5% of patients in the enoxaparin group. The incidence of drug-related adverse events, mainly gastrointestinal, was 12.0% in the rivaroxaban group and 13.0% in the enoxaparin group.
Conclusions
Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding. (ClinicalTrials.gov number, NCT00361894.)
Media in This Article
Figure 1
Enrollment, Randomization, and Follow-up of the Study Patients.Table 1
Inclusion and Exclusion of the Study Participants Who Underwent Randomization.Article Activity
- Article
Venous thromboembolism is a major, potentially fatal complication after major orthopedic surgery such as total knee arthroplasty.1 Anticoagulants that are currently used for thromboprophylaxis require parenteral administration or have unpredictable pharmacodynamic properties that require monitoring.2 Several anticoagulants currently in development target individual coagulation factors, including thrombin and activated factor X (factor Xa). The efficacy of the parenterally administered indirect factor Xa inhibitor fondaparinux for thromboprophylaxis encouraged the development of direct factor Xa inhibitors.3
Rivaroxaban (Xarelto, Bayer HealthCare) is an orally active direct factor Xa inhibitor.4 Phase 2 studies showed that rivaroxaban was potentially safe and effective for thromboprophylaxis after major orthopedic surgery across a wide range of doses.5-8 Total daily doses of 5 to 20 mg of rivaroxaban had efficacy and safety similar to those of enoxaparin after total hip arthroplasty and total knee arthroplasty.6,7 A subsequent study indicated that rivaroxaban at a dose of 10 mg once daily had sufficient efficacy and safety to merit further investigation.8
Here, we describe a multicenter, randomized, double-blind trial that compared the efficacy and safety of oral rivaroxaban, 10 mg once daily, administered postoperatively, with those of enoxaparin, 40 mg given subcutaneously once daily, administered preoperatively, for the prevention of venous thromboembolism after elective total knee arthroplasty.
Methods
Patients
Patients were eligible for the study if they were 18 years of age or older and were scheduled for total knee arthroplasty. We excluded patients with active bleeding or a high risk of bleeding that contraindicated the use of low-molecular-weight heparin and patients with any contraindication to the use of enoxaparin or with any contraindication necessitating adjustment of its dose. Other exclusion criteria included conditions preventing bilateral venography, clinically significant liver disease, concomitant use of protease inhibitors of the human immunodeficiency virus or fibrinolytic agents, planned intermittent pneumatic compression, requirement of ongoing anticoagulant therapy, and pregnancy or breast-feeding.
Study Design and Medications
On a double-blind and double-dummy basis, before surgery, patients were randomly assigned through a central telephone system to receive once-daily oral rivaroxaban (Bayer HealthCare), in a 10-mg tablet, or a once-daily injection of enoxaparin sodium (Clexane or Lovenox, Sanofi-Aventis), in a 40-mg dose. Enoxaparin was initiated 12 hours before surgery and was given again 6 to 8 hours after wound closure. Rivaroxaban was initiated 6 to 8 hours after wound closure. Thereafter, the study medication was administered every 24 hours.
The day of surgery was defined as day 1, and study medications were continued until at least day 10 and up to day 14. Patients underwent mandatory, bilateral venography between day 11 and day 15. No further study medication was given after venography; further thromboprophylaxis was given at the investigator's discretion, according to the local practice. Patients were followed for 30 to 35 days after the last dose of study medication.
The trial was performed in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committee or institutional review board of each center, and written informed consent was obtained from each patient before randomization.
The study was designed and supervised by the Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD3) Steering Committee (see the Appendix). Data were collected and analyzed by the study sponsors. The Steering Committee wrote the first draft of the manuscript and made the decision to publish. All authors contributed to writing the manuscript, had full access to the data and analyses, and vouch for the report's accuracy and completeness.
Outcome Measures
All outcomes were assessed by central, independent adjudication committees who were unaware of the treatment assignments. The primary outcome was the composite of any deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause within 13 to 17 days after surgery. The main secondary efficacy outcome was major venous thromboembolism (i.e., proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death related to venous thromboembolism). Other efficacy outcomes included the incidence of deep-vein thrombosis (any, proximal, or distal), symptomatic venous thromboembolism occurring during the treatment period or follow-up period, and death during the follow-up period.
Deep-vein thrombosis was assessed between day 11 and day 15, or earlier if symptoms were present, by means of ascending, bilateral venography.9 In cases of suspected deep-vein thrombosis, ultrasonography or venography was used to confirm the diagnosis. In cases of suspected pulmonary embolism, ventilation–perfusion scintigraphy of the lung and chest radiography or spiral computed tomography were performed, or pulmonary angiography was performed. Autopsies were planned if a participant died.
The main safety outcome was the incidence of major bleeding occurring between intake of the first dose of study medication and 2 days after the last dose. Major bleeding was defined as bleeding that was fatal, that involved a critical organ, or that required reoperation or clinically overt bleeding outside the surgical site that was associated with a decrease in the hemoglobin level of 2 g or more per deciliter or requiring infusion of 2 or more units of blood. Other safety outcomes included any bleeding or major bleeding occurring between intake of the first dose of study medication and 2 days after the last dose, nonmajor bleeding including hemorrhagic wound complications (excessive wound hematoma or bleeding at the surgical site), other adverse events, and death. Laboratory variables and cardiovascular adverse events were monitored during the treatment and follow-up periods.
Statistical Analysis
We aimed to determine whether the efficacy of rivaroxaban was noninferior to that of enoxaparin in the per-protocol population and, if so, to determine whether rivaroxaban had superior efficacy to enoxaparin in the modified intention-to-treat population. The modified intention-to-treat population included all patients who had undergone surgery, who took a study medication, and who had an adequate assessment for thromboembolism. These patients were included in the per-protocol analysis if their records showed no major protocol violations. The safety analysis included all patients who received at least one dose of a study medication.
For the primary efficacy analysis, we estimated the difference between the incidences in the rivaroxaban group and the enoxaparin group, after stratification on the basis of country of the center, using Mantel–Haenszel weighting; the corresponding asymptotic two-sided 95% confidence interval was also reported. Tests for noninferiority and superiority were both based on 95% confidence intervals. For the primary efficacy outcome, the threshold for the noninferiority test was an absolute difference between the two groups of 4%. The superiority test for major venous thromboembolism was preceded by a noninferiority test (absolute margin, 1.5%). Unweighted exact methods were used to assess secondary outcomes that occurred infrequently (e.g., pulmonary embolism and death).
For the test of superiority, on the basis of an assumed event rate of 27% in the enoxaparin group, we calculated that 860 patients per treatment group would be sufficient to detect a relative risk reduction of 25% in the rivaroxaban group as compared with the enoxaparin group, with a statistical power of 90% and a two-sided type I error rate of 5%. With the assumption of an inadequate assessment of venous thromboembolism in 25% of participants, the total number of patients was increased to 2300.
In the two-step statistical analysis we performed, a noninferiority test (based on a noninferiority limit of 4 percentage points) preceding the superiority test had a statistical power of 91% if we assumed an absolute risk reduction of 3% (corresponding to a relative risk reduction of 11%) in the rivaroxaban group as compared with the enoxaparin group. If the absolute risk reduction was assumed to be only 2% (corresponding to a relative risk reduction of 7%), a statistical power of 80% would be maintained.
The difference in the incidence of major bleeding between the rivaroxaban group and the enoxaparin group was analyzed with the same methods for efficacy; other safety outcomes were analyzed by means of appropriate descriptive methods. Sex and race were analyzed with the use of a Cochran–Mantel–Haenszel test adjusted for country. Age, weight, and body-mass index were analyzed by means of two-way analysis of variance, with treatment group and country as fixed effects. All other variables were analyzed descriptively, and statistical tests were performed with the use of a two-sided type I error rate of 5%.
Results
Study Populations
Between February 2006 and November 2006, 2556 patients were enrolled in 147 centers in 19 countries (Figure 1Figure 1
Enrollment, Randomization, and Follow-up of the Study Patients.). Reasons for exclusion were similar between the rivaroxaban and enoxaparin groups (Table 1Table 1Inclusion and Exclusion of the Study Participants Who Underwent Randomization.). Baseline characteristics were well balanced between the two groups except for a slight excess of women in the rivaroxaban group (P=0.03) (Table 2Table 2
Baseline Characteristics of the 2459 Patients in the Safety Population.). The mean duration of therapy was 11.9 days with rivaroxaban and 12.5 days with enoxaparin.Efficacy Outcomes
The primary efficacy outcome occurred in 79 of 824 patients (9.6%) in the rivaroxaban group and in 166 of 878 (18.9%) in the enoxaparin group (weighted absolute risk reduction, 9.2%; 95% confidence interval [CI], 5.9 to 12.4; P<0.001; relative risk reduction, 49%; 95% CI, 35 to 61; P<0.001) (Table 3Table 3
Incidence of Events for Efficacy Analysis.). Rivaroxaban was noninferior to enoxaparin (P<0.001 for the noninferiority analysis; data not shown).Major venous thromboembolism occurred in 9 of 908 patients (1.0%) in the rivaroxaban group and 24 of 925 (2.6%) in the enoxaparin group (weighted absolute risk reduction, 1.6%; 95% CI, 0.4 to 2.8; P=0.01; relative risk reduction, 62%; 95% CI, 18 to 82; P=0.02) (Table 3).
Among the 2418 patients who were validated for the safety analysis and who underwent surgery, the incidence of symptomatic venous thromboembolic events was lower in the rivaroxaban group (8 of 1201 patients [0.7%]) than in the enoxaparin group (24 of 1217 patients [2.0%]; weighted absolute risk reduction, 1.3%; 95% CI, 0.4 to 2.2; P=0.005; relative risk reduction, 66%; 95% CI, 25 to 85; P=0.008) (Table 3). The incidence of symptomatic venous thromboembolism during the follow-up period was similar in the two groups (Table 3). During the treatment period, there were no deaths or known pulmonary emboli in the rivaroxaban group and two unexplained deaths and four known pulmonary emboli in the enoxaparin group; during the follow-up period, there were four unexplained deaths in the enoxaparin group.
Safety
Major bleeding occurred in 7 of 1220 patients (0.6%) who received rivaroxaban and 6 of 1239 (0.5%) who received enoxaparin (weighted absolute risk increase, 0.1%; P=0.77) (Table 4Table 4
Safety Outcomes.). No episodes of fatal bleeding occurred. There were three cases of hemorrhagic spinal puncture without neurologic signs or symptoms of compression: one occurred in the rivaroxaban group before the first dose was administered, and two occurred in the enoxaparin group. The combined incidence of major and clinically relevant nonmajor bleeding events was similar in the two groups (40 of 1220 patients [3.3%] in the rivaroxaban group and 34 of 1239 patients [2.7%] in the enoxaparin group, P=0.44). There was no significant difference between the two groups in postoperative drainage or transfusion requirement (Table 4).The adverse-event profiles of rivaroxaban and enoxaparin were similar (Table 4 and the Supplementary Appendix, available with the full text of this article at www.nejm.org); the most commonly reported events in both groups included nausea, vomiting, and constipation. The incidences of serious events and serious drug-related events were also similar in the two groups during treatment. There were six deaths (0.5%) during the entire study, all in the enoxaparin group. Alanine aminotransferase levels were elevated to three times the upper limit of the normal range in 20 of 1150 patients (1.7%) who were receiving rivaroxaban and in 20 of 1156 patients (1.7%) who were receiving enoxaparin; two of these patients in the rivaroxaban group also had serum bilirubin levels that were more than twice the upper limit of the normal range. In all these patients, the increased levels of alanine aminotransferase and bilirubin returned to normal with continued treatment. The incidence of adverse cardiovascular events during therapy was low and was similar between the two groups (Table 4). During the follow-up period, there were no cardiovascular events in the rivaroxaban group and seven events in six patients receiving enoxaparin.
Discussion
In this trial of thromboprophylaxis after total knee arthroplasty, we found that rivaroxaban, an orally active direct inhibitor of factor Xa, was more effective than enoxaparin in preventing venous thrombosis, with similar rates of bleeding. Rivaroxaban reduced the absolute risk of the composite of deep-vein thrombosis, nonfatal pulmonary embolism, and death from any cause by 9.2%, and the risk of major venous thromboembolism by 1.6%, as compared with enoxaparin. The absolute risk reduction in the incidence of clinically important, symptomatic venous thromboembolic events was also greater with rivaroxaban than enoxaparin (absolute risk reduction, 1.3%). There were no pulmonary emboli or deaths in patients receiving rivaroxaban; in the enoxaparin group, four patients had a pulmonary embolus and an additional two died.
Rivaroxaban and enoxaparin had similar safety profiles. There were no clinically significant differences in the incidence of bleeding or other safety outcomes between the two groups. Major bleeding occurred in 0.6% of patients in the rivaroxaban group and in 0.5% of patients in the enoxaparin group. These rates are in line with the rates found in similar trials.10,11 Bleeding was defined in this trial as bleeding occurring after the intake of the first blinded dose of study medication. In the rivaroxaban group, bleeding that occurred during or shortly after surgery was included (1 major bleeding event and 10 nonmajor bleeding events), even though rivaroxaban had not been administered. This design resulted in a conservative estimate of the incidence of bleeding with rivaroxaban. Elevations of alanine aminotransferase and bilirubin levels, found in less than 2% of patients in both groups, were transient and returned to normal during treatment, as has been found in other trials.6-8,12
There is a risk of reactivation of coagulation on cessation of anticoagulant treatment, which may manifest as an increase in adverse cardiovascular events.13 Such events (cardiovascular death, myocardial infarction, ischemic stroke, or unexplained death) were specifically monitored and centrally adjudicated as a safety outcome. None occurred after cessation of treatment with rivaroxaban (with seven such events occurring in the enoxaparin group).
The strengths of this trial include the number of patients enrolled — more than in similar trials conducted with fondaparinux or ximelagatran.10,11,14 The large number of nonwhite patients enrolled and the low number of excluded concomitant medications allow these findings to be applied widely. The incidence of deep-vein thrombosis in the enoxaparin group (18.2%) was consistent with the incidence in contemporary clinical trials of the direct factor Xa inhibitors razaxaban (15.9% of patients given enoxaparin)15 and apixaban (15.6% of patients given enoxaparin).16 The incidence of major venous thromboembolism (the composite of proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death related to venous thromboembolism) among patients receiving enoxaparin was 2.2%17 and 3.1%,18 in studies investigating dabigatran and ximelagatran, respectively, as compared with 2.6% in this trial — suggesting that enoxaparin performed well in this trial.
In agreement with other phase 3 studies of thromboprophylaxis in patients undergoing major orthopedic surgery, the population used for the efficacy analysis did not include patients with an inadequate venographic assessment for the presence or absence of deep-vein thrombosis.19,20 In our study, 67% of patients who underwent randomization were included in the modified intention-to-treat population. However, because the number of valid venograms was lower than expected, the steering committee (which was unaware of the treatment assignments) increased recruitment from the planned 2300 patients to more than 2500 to maintain the statistical power of the trial. To support the findings for the primary efficacy outcome, several sensitivity analyses were performed to ensure that missing data did not bias the outcome. All these analyses support the main finding of the study: a significant reduction in the incidence of the primary outcome with rivaroxaban, as compared with enoxaparin, with the exception of the most conservative assumption (i.e., that all patients with an inadequate assessment of thromboembolism were assumed to have had an event).
However, all patients were followed clinically and were included in the evaluation of symptomatic venous thromboembolism (see the Supplementary Appendix). All adjudicated events — positive venograms, symptomatic events, and deaths — and all venograms that could be evaluated and that were adjudicated to show no deep-vein thrombosis were considered, irrespective of whether they occurred outside the predefined time windows. The weighted absolute risk reduction for the primary outcome with rivaroxaban, as compared with enoxaparin, was 8.9% (95% CI, 5.6 to 12.2). Moreover, when all assessments by investigators that could be evaluated (when the assessment by the central adjudication committee could not be) were also included in the analysis, the weighted absolute risk reduction was 8.1%, in favor of rivaroxaban (95% CI, 4.9 to 11.2).
The optimal absolute risk margin for noninferiority studies is still debated. The margin has to be viewed in relation to the expected efficacy rate in the comparison group and to the clinical implication. Given the efficacy data from the phase 2 studies of rivaroxaban and the contemporary data on the comparison group, we found that a margin of 4 percentage points was acceptable. In this study, rivaroxaban was superior to enoxaparin, making the question of noninferiority moot.
We conducted our trial using the enoxaparin dose and regimen (40 mg once daily) approved for use in Europe, not the regimen (30 mg twice daily) approved for use after total knee arthroplasty in the United States. However, a trial is being conducted to compare rivaroxaban with the 30-mg, twice-daily dose of enoxaparin given before surgery in patients undergoing total knee arthroplasty.
In conclusion, this trial of thromboprophylaxis after total knee replacement found that rivaroxaban, an orally effective direct factor Xa inhibitor, given in a fixed, unmonitored, once-daily dose, was superior to enoxaparin in preventing venous thrombosis, with similar rates of bleeding. Rivaroxaban merits further investigation for its ability to prevent venous thrombosis.
Supported by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development.
All the authors report receiving honoraria from Bayer HealthCare as members of the RECORD3 steering committee and consulting fees from Bayer HealthCare; Drs. Lassen, Ageno, Borris, Lieberman, and Roschencher, advisory board fees from Bayer HealthCare; Drs. Lassen, Borris, and Turpie, consulting fees from Sanofi-Aventis; Drs. Bandel and Misselwitz, being employees of Bayer HealthCare; Dr. Misselwitz, holding equity and stock options in Bayer HealthCare and being the coauthor of one rivaroxaban patent; and Dr. Turpie, receiving consulting fees from Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development.
No other potential conflict of interest relevant to this article was reported.
We thank Toby Allinson and Clare Ryles for editorial assistance in the preparation of a previous draft of the manuscript, with funding from Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development.
Source Information
From Nordsjællands Hospital, Hørsholm, Denmark (M.R.L.); University of Insubria, Varese, Italy (W.A.); Aarhus University Hospital, Aarhus, Denmark (L.C.B.); Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington (J.R.L.); Paris Descartes University, Cochin Hospital, Paris (N.R.); Bayer HealthCare, Wuppertal, Germany (T.J.B., F.M.); and McMaster University, Hamilton, ON, Canada (A.G.G.T.).
Address reprint requests to Dr. Lassen at the Department of Orthopedic Surgery, Nordsjællands Hospital, Usserd Kongevej 102, DK-2970 Hørsholm, Denmark, or at mirula@noh.regionh.dk.
The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD3) study group and investigators are listed in the Appendix.
Appendix
The members of the RECORD3 study group were as follows: Steering Committee — M.R. Lassen (chair), W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, A.G.G. Turpie, and K. Harris and M. Lederman (nonvoting members); Independent Central Adjudication Committee — M. Levine; Venous Thromboembolic Event Adjudication Committee — H. Eriksson, G. Sandgren, J. Wallin; Cardiovascular Adverse Event Adjudication Committee — J.P. Bassand, C. Bode, T. Lüscher; Bleeding Event Adjudication Committee — U. Angeras, A. Falk, M. Prins; Data and Safety Monitoring Board — H. Bounameaux, S. Dittmar (sponsor contact), D. Larray, W. Lehmacher (independent statistician), A. Leizorovicz; Sponsor, Bayer HealthCare —A. Benson (statistical analysis); A. Duszczyszyn (study management); M. Lederman (medical expert). The RECORD3 investigators were as follows (with the numbers of patients enrolled at each site in parantheses): Austria (89) — J. Hochreiter, G. Labek, R. Windhager, P. Zenz; Belgium (134) — T. Borms, C. Brabants, P. Gunst, W. Henkes, H. Mortele, E. Vandermeersch, D. Vanlommel, B. Willems; Canada (137) — F. Abuzgaya, D. Armstrong, E. Dessouki, C. Dobson, S. Dolan, P. Grosso, G. Jasey, J. Naude, E. Wai, P. Zalzal; China (162) — T. Chen, H. Lv, Y. Wang, Q. Yang, B. Zeng, H. Zhang; Colombia (100) — B. Aguilera, R. Botero, A. Reyes; Czech Republic (176) — I. Kofranek, K. Koudela, M. Krbec, P. Kubat, J. Kubes, J. Sedivy, O. Stano, O. Vins; Denmark (139) — O.A. Borgwardt, P. Joergensen, M.R. Lassen, G. Lausten, S. Mikkelsen; France (154) — M. Carles, P. Chaussis, J.M. Debue, E. Eisenberg, C. Forestier, J.P. Franceschi, E. Gaertner, G. Hennion, T. Lazard, D. Lugrin, P. Macaire, X. Maschino, Y. Matuszczak, J.P. Moulinie, A. Peron; Germany (190) — W. Birkner, J. Eulert, H.M. Fritsche, A. Halder, T. Horacek, F. Kleinfeld, R. Krauspe, A. Kurth, P. Mouret, B. Muehlbauer, H. Schmelz; Israel (143) — V. Benkovich, B. Brenner, S. Dekel, M. Elias, N. Halperin, D. Hendel, U. Martinowitz, M. Nyska, I. Otremski; Italy (179) — B. Borghi, P. Cherubino, G. Davi, G. Della Rocca, G. Fanelli, P. Grossi, M. Gusso, R. Landolfi, R. Massei, G. Melis, R. Nardacchione, P. Parise; Mexico (33) — E. Berumen Nafarr, E. Gomez Sanchez, R. Inigo Pavlovich; the Netherlands (139) — C.N. Dijk, P.A. Nolte, H.M. Schuller, R. Slappendel, J.J.J. Van der List, C.C.P.M. Verheyen, H.M. Vis; Norway (37) — K. Al-Dekany, K. Griegel, R.E. Roenning, P. Stahl, O. Talsnes; Peru (49) — F. Arrieta, R. Cotrina, L. Merzthal, E. Pastor; Poland (204) — A. Bednarek, J. Blacha, A. Gusta, J. Kruczyski, K. Kwiatkowski, P. Madyk, S. Mazurkiewi, T. Niedwiedzki, J. Skowronski, M. Synder; South Africa (143) — U. Dhanjee, J. Diedericks, J. Engelbrecht, F. Greeff, B. Jacobson, S. Moodley, H. Myburgh, R. Routier, O. Van der Spuy, L. Van Zyl; Spain (244) — R. Canosa Sevillano, A. Delgado, J.L. Diaz Almodovar, F. Gomar, X. Granero, R. Lecumberri Villamedi, A. Navarro Quiles, R. Otero Fernandez, L. Peidro Garces, Á. Salvador; Sweden (104) — L. Ahnfelt, B. Edshage, B.I. Eriksson, M. Flondell, H. Laestander, S. Lind, B. Paulsson, A. Wykman.
- References
References
1
Geerts WH ,Pineo GF ,Heit JA , et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl:338S-400S
CrossRef | Web of Science | Medline2
Turpie AG . Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-1247
CrossRef | Web of Science | Medline3
Turpie AG ,Bauer KA ,Eriksson BI ,Lassen MR . Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-1840
CrossRef | Web of Science | Medline4
Perzborn E ,Strassburger J ,Wilmen A , et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -- an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-521
CrossRef | Web of Science | Medline5
Eriksson BI ,Borris LC ,Dahl OE , et al. Dose-escalation study of rivaroxaban (BAY 59-7939) -- an oral, direct Factor Xa inhibitor -- for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 2007;120:685-693
CrossRef | Web of Science | Medline6
Eriksson BI ,Borris L ,Dahl OE , et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-128
CrossRef | Web of Science | Medline7
Turpie AG ,Fisher WD ,Bauer KA , et al. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005;3:2479-2486
CrossRef | Web of Science | Medline8
Eriksson BI ,Borris LC ,Dahl OE , et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-2381
CrossRef | Web of Science | Medline9
Rabinov K ,Paulin S . Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-144
CrossRef | Web of Science | Medline10
Colwell CW Jr ,Berkowitz SD ,Lieberman JR , et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005;87:2169-2177
CrossRef | Web of Science | Medline11
Bauer KA ,Eriksson BI ,Lassen MR ,Turpie AG . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310
Full Text | Web of Science | Medline12
Agnelli G ,Gallus A ,Goldhaber SZ , et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007;116:180-187
CrossRef | Web of Science | Medline13
Hermans C ,Claeys D . Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin 2006;22:471-481
CrossRef | Web of Science | Medline14
Francis CW ,Berkowitz SD ,Comp PC , et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-1712
Full Text | Web of Science | Medline15
Lassen MR ,Davidson BL ,Gallus A ,Pineo G ,Ansell J ,Deitchman D . A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2003;102:15a-15a
Web of Science16
Lassen MR ,Davidson BL ,Gallus A ,Pineo G ,Ansell J ,Deitchman D . A phase II randomized, double-blind, eight-arm, parallel-group, dose-response study of apixaban, a new oral factor Xa inhibitor for the prevention of deep vein thrombosis in knee replacement surgery. Blood 2006;108:173a-173a
Web of Science17
Friedman RJ ,Caprini JA ,Comp PC , et al. Dabigatran etexilate versus enoxaparin in preventing venous thromboembolism following total knee arthroplasty. J Thromb Haemost 2007;5:Suppl 1-Suppl 118
Heit JA ,Colwell CW ,Francis CW , et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001;161:2215-2221
CrossRef | Web of Science | Medline19
Comp PC ,Spiro TE ,Friedman RJ , et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone Joint Surg Am 2001;83:336-345
Web of Science | Medline20
Eriksson BI ,Dahl OE ,Rosencher N , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007;370:949-956
CrossRef | Web of Science | Medline
- Citing Articles (220)
Citing Articles
1
Jacques E. Chelly. (2012) Thromboprophylaxis and Regional Anesthesia in the Ambulatory Setting. International Anesthesiology Clinics 49:4, 166-173
CrossRef2
Jawed Fareed, Indermohan Thethi, Debra Hoppensteadt. (2012) Old Versus New Oral Anticoagulants: Focus on Pharmacology. Annual Review of Pharmacology and Toxicology 52:1, 79-99
CrossRef3
Rupert M. Bauersachs. (2012) Use of anticoagulants in elderly patients. Thrombosis Research 129:2, 107-115
CrossRef4
Thomas Höchtl, Kurt Huber. (2012) New anticoagulants for the prevention of stroke in atrial fibrillation. Fundamental & Clinical Pharmacology 26:1, 47-53
CrossRef5
William M. Weightman, Neville M. Gibbs. (2012) Management of coagulation. Current Opinion in Anaesthesiology 25:1, 86-95
CrossRef6
Aurea Duran, Nishan Sengupta, Alexander Diamantopoulos, Fiona Forster, Louis Kwong, Michael Lees. (2012) Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payerʼs Perspective. PharmacoEconomics 30:2, 87-101
CrossRef7
Nadia Rosencher, Pierre Albaladejo. (2012) A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. Expert Opinion on Pharmacotherapy 13:2, 217-226
CrossRef8
Alexander G.G. Turpie. (2012) Rivaroxaban for the prevention and treatment of venous thromboembolism. Fundamental & Clinical Pharmacology 26:1, 33-38
CrossRef9
Sean T. Duggan. (2012) Rivaroxaban. American Journal Cardiovascular Drugs 12:1, 57-72
CrossRef10
Elena Fortuny, Jose Zamorano. (2012) Clinical evidence of the role of edoxaban in anticoagulation. Clinical Investigation 2:2, 199-206
CrossRef11
Mega, Jessica L., Braunwald, Eugene, Wiviott, Stephen D., Bassand, Jean-Pierre, Bhatt, Deepak L., Bode, Christoph, Burton, Paul, Cohen, Marc, Cook-Bruns, Nancy, Fox, Keith A.A., Goto, Shinya, Murphy, Sabina A., Plotnikov, Alexei N., Schneider, David, Sun, Xiang, Verheugt, Freek W.A., Gibson, C. Michael, . (2012) Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine 366:1, 9-19
Full Text12
Bengt I. Eriksson, Nadia Rosencher, Richard J. Friedman, Martin Homering, Ola E. Dahl. (2012) Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research
CrossRef13
David A. Garcia. (2012) Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. Thrombosis Research 129:1, 9-16
CrossRef14
Cecilia Becattini, Maria Cristina Vedovati, Giancarlo Agnelli. (2012) Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. Thrombosis Research
CrossRef15
Ferran García-Bragado Dalmau. (2012) La medicina actual ante los anticoagulantes de nueva generación. Medicina Clínica
CrossRef16
Rosa Madridejos Mora, Ester Amado Guirado. (2012) Nuevos antitrombóticos. FMC - Formación Médica Continuada en Atención Primaria 19:1, 28-35
CrossRef17
D. M. Cohn, J. Hermanides, J. H. DeVries, P.-W. Kamphuisen, S. Kuhls, M. Homering, J. B. L. Hoekstra, A. W. A. Lensing, H. R. Büller. (2012) Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Thrombosis and Haemostasis 107:2,
CrossRef18
M. M. Samama, G. Contant, T. E. Spiro, E. Perzborn, C. Guinet, Y. Gourmelin, L. Le Flem, G. Rohde, J. L. Martinoli, . (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thrombosis and Haemostasis 107:2,
CrossRef19
Dennis J. Cada, Terri L. Levien, Christopher R. Woodruff, Danial E. Baker. (2011) Formulary Drug Reviews - Rivaroxaban. Hospital Pharmacy 46:12, 960-970
CrossRef20
Pamala Kanagasabapathy, Pratima Chowdary, Alex Gatt. (2011) Alternatives to Warfarin-The Next Generation of Anticoagulants. Cardiovascular Therapeutics 29:6, e80-e88
CrossRef21
Elise S. Eerenberg, Josien van Es, Meertien K. Sijpkens, Harry R. Büller, Pieter W. Kamphuisen. (2011) New anticoagulants: Moving on from scientific results to clinical implementation. Annals of Medicine 43:8, 606-616
CrossRef22
J.-M. Baud, G. Matrand, J.-L. Georges, P. Beaufils, B. Livarek. (2011) Dépistage clinique de la thrombose veineuse profonde après prothèse de hanche et de genou. Proposition d’un score de prédiction pour guider l’indication de l’échographie-Doppler veineux. Journal des Maladies Vasculaires 36:6, 386-394
CrossRef23
Tom J. Parry, Zhihong Huang, Cailin Chen, Margery A. Connelly, Elisabeth Perzborn, Patricia Andrade-Gordon, Bruce P. Damiano. (2011) Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagulation & Fibrinolysis 22:8, 720-726
CrossRef24
Stavros Apostolakis, Gregory YH Lip, Deirdre A Lane, Eduard Shantsila. (2011) The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. Cardiovascular Therapeutics 29:6, e12-e22
CrossRef25
Ann K Wittkowsky. (2011) Novel Oral Anticoagulants and Their Role in Clinical Practice. Pharmacotherapy 31:12, 1175-1191
CrossRef26
Aurea Duran, Nishan Sengupta, Alexander Diamantopoulos, Fiona Forster, Louis Kwong, Michael Lees. (2011) Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer’s perspective. Journal of Medical Economics 14:6, 824-834
CrossRef27
T. T. Horlocker. (2011) Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy. British Journal of Anaesthesia 107:suppl 1, i96-i106
CrossRef28
Anja Kaeberich, Iris Reindl, Uwe Raaz, Lars Maegdefessel, Alexander Vogt, Torsten Linde, Ulrich Steinseifer, Elisabeth Perzborn, Baerbel Hauroeder, Michael Buerke, Karl Werdan, Axel Schlitt. (2011) Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. Journal of Thrombosis and Thrombolysis 32:4, 417-425
CrossRef29
Michelle T. Martin, Edith A. Nutescu. (2011) Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. Current Medical Research and Opinion 27:11, 2123-2131
CrossRef30
Vinai C. Bhagirath, Lauren O'Malley, Mark A. Crowther. (2011) Management of Bleeding Complications in the Anticoagulated Patient. Seminars in Hematology 48:4, 285-294
CrossRef31
Wolfgang Mueck, Anthonie W.A. Lensing, Giancarlo Agnelli, Hervé Decousus, Paolo Prandoni, Frank Misselwitz. (2011) Rivaroxaban. Clinical Pharmacokinetics 50:10, 675-686
CrossRef32
Vincenzo Toschi, Maddalena Lettino. (2011) Inhibitors of propagation of coagulation: factors V and X. British Journal of Clinical Pharmacology 72:4, 563-580
CrossRef33
Rashid S. Kazmi, Bashir A. Lwaleed. (2011) New anticoagulants: how to deal with treatment failure and bleeding complications. British Journal of Clinical Pharmacology 72:4, 593-603
CrossRef34
M. Delbeck, K. F. Nickel, E. Perzborn, P. Ellinghaus, J. Strassburger, R. Kast, V. Laux, S. Schafer, R. T. Schermuly, G. von Degenfeld. (2011) A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovascular Research 92:1, 159-168
CrossRef35
Richard J. Friedman. (2011) Novel Oral Anticoagulants for VTE Prevention in Orthopedic Surgery: Overview of Phase 3 Trials. Orthopedics 34:10, 795-804
CrossRef36
Lars Ryttberg, Alex Diamantopoulos, Fiona Forster, Michael Lees, Anina Fraschke, Ingela Björholt. (2011) Cost–effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Review of Pharmacoeconomics & Outcomes Research 11:5, 601-615
CrossRef37
L. Bertoletti, P. Mismetti. (2011) Les nouveaux anticoagulants dans la maladie thrombo-embolique veineuse. Revue des Maladies Respiratoires 28:8, 1008-1016
CrossRef38
Estella M Davis, Kathleen A Packard, Jon T Knezevich, Jennifer A Campbell. (2011) New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome. Pharmacotherapy 31:10, 975-1016
CrossRef39
Patel, Manesh R., Mahaffey, Kenneth W., Garg, Jyotsna, Pan, Guohua, Singer, Daniel E., Hacke, Werner, Breithardt, Günter, Halperin, Jonathan L., Hankey, Graeme J., Piccini, Jonathan P., Becker, Richard C., Nessel, Christopher C., Paolini, John F., Berkowitz, Scott D., Fox, Keith A.A., Califf, Robert M., the ROCKET AF Steering Committee. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine 365:10, 883-891
Full Text40
Taki Galanis, Walter K. Kraft, Geno J. Merli. (2011) Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient. Advances in Surgery 45:1, 361-390
CrossRef41
D. MARATEA, V. FADDA, S. TRIPPOLI, A. MESSORI. (2011) Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. Journal of Thrombosis and Haemostasis 9:9, 1868-1870
CrossRef42
Tina Scoble, Sonali Wijetilleka, Munther A. Khamashta. (2011) Management of refractory anti-phospholipid syndrome. Autoimmunity Reviews 10:11, 669-673
CrossRef43
Thomas Goff, George Kontakis, Peter V Giannoudis. (2011) Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update. Expert Opinion on Drug Safety 10:5, 687-696
CrossRef44
Benjamin Brenner, Ron Hoffman. (2011) Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Reviews 25:5, 215-221
CrossRef45
M. LEVI, E. EERENBERG, P. W. KAMPHUISEN. (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. Journal of Thrombosis and Haemostasis 9:9, 1705-1712
CrossRef46
Kan He, Joseph M. Luettgen, Donglu Zhang, Bing He, James E. Grace, Baomin Xin, Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb, Patrick Y. S. Lam, Ruth R. Wexler, Scott J. Grossman. (2011) Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. European Journal of Drug Metabolism and Pharmacokinetics 36:3, 129-139
CrossRef47
Taki Galanis, Geno J. Merli. 2011. Newer Oral Anticoagulants. , 67-80.
CrossRef48
J. Steffel, E. Braunwald. (2011) Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal 32:16, 1968-1976
CrossRef49
L.M. Asmis, L. Alberio, A. Angelillo-Scherrer, W. Korte, A. Mendez, G. Reber, B. Seifert, H. Stricker, D.A. Tsakiris, W.A. Wuillemin. (2011) Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests. Thrombosis Research
CrossRef50
Renato D. Lopes, Richard C. Becker, John H. Alexander, Paul W. Armstrong, Robert M. Califf, Mark Y. Chan, Mark Crowther, Christopher B. Granger, Robert A. Harrington, Elaine M. Hylek, Stefan K. James, E. Marc Jolicoeur, Kenneth W. Mahaffey, L. Kristin Newby, Eric D. Peterson, Karen S. Pieper, Frans Werf, Lars Wallentin, Harvey D. White, Antonio C. Carvalho, Roberto R. Giraldez, Helio P. Guimaraes, Helena B. Nader, Renato A. K. Kalil, Joyce M. A. Bizzachi, Antonio C. Lopes, David A. Garcia. (2011) Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis 32:2, 242-266
CrossRef51
A. John Camm, Henri Bounameaux. (2011) Edoxaban. Drugs 71:12, 1503-1526
CrossRef52
M. M. Samama, G. Gerotziafas. (2011) Trois nouveaux anticoagulants disponibles en 2011: Dabigatran Etexilate, Rivaroxaban et Apixaban. Bio tribune magazine 38:1, 10-15
CrossRef53
Maryam Sattari, David T Lowenthal. (2011) Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban. American Journal of Therapeutics 18:4, 332-338
CrossRef54
Alessandro Squizzato, Elena Rancan, Francesco Dentali. (2011) Pharmacotherapy of deep-venous thrombosis: current status and future perspective. Clinical Investigation 1:7, 1039-1047
CrossRef55
Menno V. Huisman. (2011) The proof for new oral anticoagulants: clinical trial evidence. European Orthopaedics and Traumatology 2:1-2, 7-14
CrossRef56
K. A. BAUER. (2011) Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. Journal of Thrombosis and Haemostasis 9, 12-19
CrossRef57
Thomas G. DeLoughery. (2011) Practical aspects of the oral new anticoagulants. American Journal of Hematology 86:7, 586-590
CrossRef58
O. Cousin, C. Le Hello, M.-T. Barrellier. (2011) Incidence et distribution des thromboses veineuses des membres inférieurs diagnostiquées par écho-doppler au décours de prothèses de hanche, de genou et de fractures de hanche. Résultats portant sur 5981 explorations et 2123 thromboses en dix ans. Journal des Maladies Vasculaires 36:4, 243-253
CrossRef59
Ramon A Partida, Robert P Giugliano. (2011) Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiology 7:4, 459-470
CrossRef60
Luca Masotti, Mario Di Napoli, Daniel A. Godoy, Daniela Rafanelli, Giancarlo Liumbruno, Nicholas Koumpouros, Giancarlo Landini, Alessandro Pampana, Roberto Cappelli, Daniela Poli, Domenico Prisco. (2011) The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. International Journal of Stroke 6:3, 228-240
CrossRef61
Richard J Friedman, Nishan Sengupta, Michael Lees. (2011) Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Review of Pharmacoeconomics & Outcomes Research 11:3, 299-306
CrossRef62
Meyer Michel Samama. (2011) The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thrombosis Research 127:6, 497-504
CrossRef63
Sam Schulman, Ammar Majeed. (2011) A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery. Drug Safety 34:6, 449-463
CrossRef64
Song Turun, Liao Banghua, Yin Yuan, Li Zhenhui, Nie Ying, Chen Jin. (2011) A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thrombosis Research 127:6, 525-534
CrossRef65
Deepu Alexander, Allen Jeremias. (2011) Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opinion on Investigational Drugs 20:6, 849-857
CrossRef66
Mátyás Keltai, Katalin Keltai. (2011) Új antikoagulánsok a vénás thromboembolia megelőzésében és kezelésében. Orvosi Hetilap 152:25, 983-992
CrossRef67
Geneviève Freyburger, Gérard Macouillard, Sylvie Labrouche, François Sztark. (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement. Thrombosis Research 127:5, 457-465
CrossRef68
Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson. (2011) Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. Journal of Thrombosis and Thrombolysis 31:4, 407-416
CrossRef69
C. Michael Gibson, Jessica L. Mega, Paul Burton, Shinya Goto, Freek Verheugt, Christoph Bode, Alexei Plotnikov, Xiang Sun, Nancy Cook-Bruns, Eugene Braunwald. (2011) Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. American Heart Journal 161:5, 815-821.e6
CrossRef70
Zafar Iqbal, Marc Cohen. (2011) Enoxaparin: a pharmacologic and clinical review. Expert Opinion on Pharmacotherapy 12:7, 1157-1170
CrossRef71
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti. (2011) Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders. Clinical Investigation 1:5, 725-737
CrossRef72
Bénédicte Dumont, Dorothée Faille, Nadine Ajzenberg. (2011) Les nouveaux anticoagulants oraux. médecine/sciences 27:5, 493-500
CrossRef73
Charles Marc Samama, Anne Godier. (2011) Perioperative deep vein thrombosis prevention: what works, what does not work and does it improve outcome?. Current Opinion in Anaesthesiology 24:2, 166-170
CrossRef74
Taki Galanis, Lynda Thomson, Michael Palladino, Geno J. Merli. (2011) New oral anticoagulants. Journal of Thrombosis and Thrombolysis 31:3, 310-320
CrossRef75
Francisco Gabriel Botella, Manuel Labiós Gómez, Blanca Navarro Cubells. (2011) Nuevos anticoagulantes orales en la prevención de la enfermedad tromboembólica venosa. Medicina Clínica 136:12, 553-554
CrossRef76
Shaker A. Mousa. (2011) The Future of Anticoagulant Therapy. Cardiovascular Therapeuticsno-no
CrossRef77
Seung-Ho Kang, Yuman Ryu. (2011) The Adjustment of the Type I Error Rate in Noninferiority Trials with λ-Margin Approach: Each of Two Different New Drugs is Approved with Two Independent Trials with the Same Active Control. Journal of Biopharmaceutical Statistics 21:3, 498-510
CrossRef78
Yu-Kai Lee, Mark R. Player. (2011) Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Medicinal Research Reviews 31:2, 202-283
CrossRef79
Frank Misselwitz, Scott D. Berkowitz, Elisabeth Perzborn. (2011) The discovery and development of rivaroxaban. Annals of the New York Academy of Sciences 1222:1, 64-75
CrossRef80
Pier Mannuccio Mannucci, Massimo Franchini. (2011) Old and new anticoagulant drugs: A minireview. Annals of Medicine 43:2, 116-123
CrossRef81
F. Randelli, F. Biggi, G. Della Rocca, P. Grossi, D. Imberti, R. Landolfi, G. Palareti, D. Prisco. (2011) Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. Journal of Orthopaedics and Traumatology 12:1, 69-76
CrossRef82
Aaron M. From, Deana D. Hoganson, Patricia J. Erwin. (2011) Does a longer duration of oral factor Xa therapy increase the risk of bleeding or transaminitis?. Thrombosis Research 127:3, 202-209
CrossRef83
Mariano A Giorgi, Hernán Cohen Arazi, Claudio D Gonzalez, Guillermo Di Girolamo. (2011) Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert Opinion on Pharmacotherapy 12:4, 567-577
CrossRef84
Lars Carl Borris. (2011) Design, findings and implications of the RECORD study program. Clinical Investigation 1:3, 423-428
CrossRef85
Gentian Denas, Vittorio Pengo. (2011) Emerging anticoagulants. Expert Opinion on Emerging Drugs 16:1, 31-44
CrossRef86
K. P. CABRAL, J. ANSELL, E. M. HYLEK. (2011) Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. Journal of Thrombosis and Haemostasis 9:3, 441-449
CrossRef87
Paul B. Watkins, Mehul Desai, Scott D. Berkowitz, Gary Peters, Yves Horsmans, Dominique Larrey, Willis Maddrey. (2011) Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH). Drug Safety 34:3, 243-252
CrossRef88
Bengt I. Eriksson, Daniel J. Quinlan, John W. Eikelboom. (2011) Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. Annual Review of Medicine 62:1, 41-57
CrossRef89
Enrique Ginzburg, Franck Dujardin. (2011) Physicians’ perceptions of the definition of major bleeding in major orthopedic surgery: results of an international survey. Journal of Thrombosis and Thrombolysis 31:2, 188-195
CrossRef90
Corinne LeReun, Philip Wells, Alex Diamantopoulos, Farhat Rasul, Michael Lees, Nishan Sengupta. (2011) An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. Journal of Medical Economics 14:2, 238-244
CrossRef91
R. C. Barker, P. Marval. (2011) Venous thromboembolism: risks and prevention. Continuing Education in Anaesthesia, Critical Care & Pain 11:1, 18-23
CrossRef92
Y. K. Loke, C. S. Kwok. (2011) Dabigatran and rivaroxaban for prevention of venous thromboembolism - systematic review and adjusted indirect comparison. Journal of Clinical Pharmacy and Therapeutics 36:1, 111-124
CrossRef93
Susanne Lison, Michael Spannagl. (2011) Monitoring of direct anticoagulants. Wiener Medizinische Wochenschrift 161:3-4, 58-62
CrossRef94
Charles Marc Samama. (2011) New anticoagulants: pharmacology and clinical studies. Wiener Medizinische Wochenschrift 161:3-4, 54-57
CrossRef95
Honorio T. Benzon. 2011. Anticoagulants and neuraxial and peripheral nerve blocks. , 629-640.
CrossRef96
Walter Lehmacher, Stephanie Wolff. (2011) Die Bedeutung von Head-to-Head-Studien für die versorgungsnahe klinische Forschung. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 105:9, 639-645
CrossRef97
Carsten Perka. (2011) Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants. Thrombosis Journal 9:1, 17
CrossRef98
Jeffrey I. Weitz. (2011) Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis Research 127, S5-S12
CrossRef99
Dhara Chaudhari, Rohit Bhuriya, Rohit Arora. (2011) Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm. American Journal of Therapeutics 18:1, e1-e11
CrossRef100
M. Levi, E. S. Eerenberg, P. W. Kampuisen. (2011) Anticoagulants. Hämostaseologie 31:4, 229-235
CrossRef101
Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Frank Misselwitz. (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nature Reviews Drug Discovery 10:1, 61-75
CrossRef102
M. H. Huo. (2011) New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?. Thrombosis and Haemostasis 106:1, 45-57
CrossRef103
S. RANGARAJAN. (2011) Inhibitors of coagulation. Haemophilia 17:1, 90-94
CrossRef104
A. G. G. Turpie, C. Esmon. (2011) Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation. Thrombosis and Haemostasis 105:4, 586-596
CrossRef105
Gregg Stashenko, Renato D. Lopes, David Garcia, John H. Alexander, Victor F. Tapson. (2011) Prophylaxis for venous thromboembolism: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 31:1, 122-132
CrossRef106
Lassen, Michael Rud, Gallus, Alexander, Raskob, Gary E., Pineo, Graham, Chen, Dalei, Ramirez, Luz Margarita, . (2010) Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. New England Journal of Medicine 363:26, 2487-2498
Full Text107
Stephan H. Schirmer, Magnus Baumhäkel, Hans-Ruprecht Neuberger, Stefan H. Hohnloser, Isabelle C. van Gelder, Gregory Y.H. Lip, Michael Böhm. (2010) Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology 56:25, 2067-2076
CrossRef108
Kurt Pfeifer, Karen F. Mauck, Steven L. Cohn, Amir K. Jaffer, Gerald W. Smetana. (2010) Update in Perioperative Medicine. Journal of General Internal Medicine 25:12, 1346-1351
CrossRef109
Timothy A. Morris. (2010) New Synthetic Antithrombotic Agents for Venous Thromboembolism: Pentasaccharides, Direct Thrombin Inhibitors, Direct Xa Inhibitors. Clinics in Chest Medicine 31:4, 707-718
CrossRef110
Julie A. Gayle, Alan D. Kaye, Adam M. Kaye, Rinoo Shah. (2010) Anticoagulants: Newer Ones, Mechanisms, and Perioperative Updates. Anesthesiology Clinics 28:4, 667-679
CrossRef111
F. Biggi, F. Randelli, G. Rocca, D. Imberti, P. Grossi, R. Landolfi, G. Palareti, D. Prisco. (2010) Consenso intersocietario sulla profilassi antitrombotica in chirurgia protesica dell’anca e del ginocchio e nelle fratture del collo femorale. LO SCALPELLO-OTODI Educational 24:3, 206-211
CrossRef112
Laura Green, Andrew S. Lawrie, Shelain Patel, Fahad Hossain, Andrew Chitolie, Ian J. Mackie, Fares S. Haddad, Samuel J. Machin. (2010) The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. British Journal of Haematology 151:5, 469-476
CrossRef113
Alessandro Squizzato, Erica Romualdi, Francesco Dentali, Walter Ageno. (2010) The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?. Current Opinion in Anaesthesiology 23:6, 722-725
CrossRef114
J. Ansell. (2010) Warfarin Versus New Agents: Interpreting the Data. Hematology 2010:1, 221-228
CrossRef115
M. Samama, J. Conard, M.-H. Horellou, L. Le Flem, C. Guinet, F. Depasse. (2010) Deux nouveaux anticoagulants disponibles en 2010 – Dabigatran Etexilate et Rivaroxaban: progrès attendus – problèmes posés. Annales Pharmaceutiques Françaises 68:6, 359-369
CrossRef116
Louis M. Kwong. (2010) Never Events and Related Quality Measures Following Total Hip and Total Knee Replacement. Orthopedics 33:11, 838-842
CrossRef117
Yong Bing Cao, Jun Dong Zhang, Hui Shen, Yuan Ying Jiang. (2010) Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology 66:11, 1099-1108
CrossRef118
Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Atef Halabi, Haidar Maatouk, Norbert Klause, Volkmar Lufft, Dominic D. Wand, Thomas Philipp, Heike Bruck. (2010) Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. British Journal of Clinical Pharmacology 70:5, 703-712
CrossRef119
S. Siebenlist, S. Haas, F. Elser, U. Stöckle. (2010) Neue orale Antikoagulanzien aus unfallchirurgischer Sicht. Der Unfallchirurg 113:11, 886-892
CrossRef120
Luke R.E. Bereznicki, Gregory M. Peterson. (2010) REVIEW: New Antithrombotics for Atrial Fibrillation. Cardiovascular Therapeutics 28:5, 278-286
CrossRef121
Marie-Thérèse Barrellier, Benoît Lebel, Jean-Jacques Parienti, Patrick Mismetti, Jean-Jacques Dutheil, Claude Vielpeau. (2010) Short versus extended thromboprophylaxis after total knee arthroplasty: A randomized comparison. Thrombosis Research 126:4, e298-e304
CrossRef122
Hans-Juergen Rupprecht, Ralf Blank. (2010) Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors. Drugs1
CrossRef123
Henrik Husted, Kristian Stahl Otte, Billy B Kristensen, Thue Ørsnes, Christian Wong, Henrik Kehlet. (2010) Low risk of thromboembolic complications after fast-track hip and knee arthroplasty. Acta Orthopaedica 81:5, 599-605
CrossRef124
Timothy K. Liem, Thanh M. Huynh, Shannon E. Moseley, Renee C. Minjarez, Gregory J. Landry, Erica L. Mitchell, Thomas G. DeLoughery, Gregory L. Moneta. (2010) Symptomatic perioperative venous thromboembolism is a frequent complication in patients with a history of deep vein thrombosis. Journal of Vascular Surgery 52:3, 651-657
CrossRef125
Karen M Hook, Charles S Abrams. (2010) Treatment options in heparin-induced thrombocytopenia. Current Opinion in Hematology 17:5, 424-431
CrossRef126
Thomas Wilke, Jörn Moock, Sabrina Müller, Matthias Pfannkuche, Andreas Kurth. (2010) Nonadherence in Outpatient Thrombosis Prophylaxis with Low Molecular Weight Heparins after Major Orthopaedic Surgery. Clinical Orthopaedics and Related Research® 468:9, 2437-2453
CrossRef127
Geno J. Merli. (2010) New Oral Antithrombotic Agents for the Prevention of Deep Venous Thrombosis and Pulmonary Embolism in Orthopedic Surgery. Orthopedics 33:9, 27-32
CrossRef128
Jonathan M. Plumb, Andreas Clemens, Brigitta U. Monz. (2010) Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement:. PharmacoEconomics 28:9, 781-782
CrossRef129
Jeremy S. Paikin, John W. Eikelboom, John A. Cairns, Jack Hirsh. (2010) New antithrombotic agents—insights from clinical trials. Nature Reviews Cardiology 7:9, 498-509
CrossRef130
O. E. DAHL, D. J. QUINLAN, D. BERGQVIST, J. W. EIKELBOOM. (2010) A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. Journal of Thrombosis and Haemostasis 8:9, 1966-1975
CrossRef131
R.J. Friedman, O.E. Dahl, N. Rosencher, J.A. Caprini, A.A. Kurth, C.W. Francis, A. Clemens, S. Hantel, J.M. Schnee, B.I. Eriksson. (2010) Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials. Thrombosis Research 126:3, 175-182
CrossRef132
Erica Romualdi, Walter Ageno. (2010) Oral Xa Inhibitors. Hematology/Oncology Clinics of North America 24:4, 727-737
CrossRef133
S. Schulman. (2010) New aspects on treatment modalities for thromboembolic episodes. Journal of Internal Medicine 268:2, 109-119
CrossRef134
Ji Zhang, Jason Crawford. 2010. Rivaroxaban (Xarelto): A Factor Xa Inhibitor for the Treatment of Thrombotic Events. , 191-205.
CrossRef135
Jonathan P Piccini, Renato D Lopes, Kenneth W Mahaffey. (2010) Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Current Opinion in Cardiology 25:4, 312-320
CrossRef136
(2010) Meeting the Unmet Needs in Anticoagulant Therapy. European Journal of Haematology 85, 1-28
CrossRef137
J. M. Walenga, C. Adiguzel. (2010) Drug and dietary interactions of the new and emerging oral anticoagulants. International Journal of Clinical Practice 64:7, 956-967
CrossRef138
C. R. Harber, M. H. Nathanson. (2010) Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery. Anaesthesia 65:6, 552-555
CrossRef139
Lars C. Borris. (2010) Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Archives of Orthopaedic and Trauma Surgery 130:5, 583-589
CrossRef140
Rickard E. Malmström. 2010. New Anticoagulants: Focus on Currently Approved Oral Factor Xa and Factor IIa Inhibitors. , 91-102.
CrossRef141
A Stanley, A Young. (2010) Primary prevention of venous thromboembolism in medical and surgical oncology patients. British Journal of Cancer 102, S10-S16
CrossRef142
Jeffrey I. Weitz. (2010) Potential of new anticoagulants in patients with cancer. Thrombosis Research 125, S30-S35
CrossRef143
Lori-Ann Linkins, Jeffrey I. Weitz. (2010) New and Emerging Anticoagulant Therapies for Venous Thromboembolism. Current Treatment Options in Cardiovascular Medicine 12:2, 142-155
CrossRef144
Rohtesh S Mehta. (2010) Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Review of Hematology 3:2, 227-241
CrossRef145
B. I. ERIKSSON, A. G. G. TURPIE, M. R. LASSEN, M. H. PRINS, G. AGNELLI, P. KÄLEBO, G. WETHERILL, J. W. WILPSHAAR, L. MEEMS, . (2010) Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). Journal of Thrombosis and Haemostasis 8:4, 714-721
CrossRef146
Gerald W. Smetana, Jane S. Sillman. (2010) Update in New Medications for Primary Care. Journal of General Internal Medicine 25:3, 261-269
CrossRef147
Montserrat Bosch Ferrer, Pilar Lalueza Broto. (2010) Nuevos anticoagulantes orales en la prevención de la enfermedad tromboembólica venosa. Medicina Clínica 134:6, 279-281
CrossRef148
Michael Rud Lassen, Gary E Raskob, Alexander Gallus, Graham Pineo, Dalei Chen, Philip Hornick. (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. The Lancet 375:9717, 807-815
CrossRef149
(2010) Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. American Heart Journal 159:3, 340-347.e1
CrossRef150
Freek W. A. Verheugt. (2010) Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nature Reviews Cardiology 7:3, 149-154
CrossRef151
Mimi L. Quan, Donald J.P. Pinto, Karen A. Rossi, Steven Sheriff, Richard S. Alexander, Eugene Amparo, Kevin Kish, Robert M. Knabb, Joseph M. Luettgen, Paul Morin, Angela Smallwood, Francis J. Woerner, Ruth R. Wexler. (2010) Phenyltriazolinones as potent factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters 20:4, 1373-1377
CrossRef152
Ann K. Wittkowsky. (2010) New oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Thrombolysis 29:2, 182-191
CrossRef153
D. Garcia, E. Libby, M. A. Crowther. (2010) The new oral anticoagulants. Blood 115:1, 15-20
CrossRef154
Richard J. Friedman. (2010) New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty. Thrombosis 2010, 1-9
CrossRef155
Richard J. Friedman. (2010) Simplifying Thromboprophylaxis Could Improve Outcomes in Orthopaedic Surgery. Thrombosis 2010, 1-5
CrossRef156
Meyer Michel Samama, Grigoris T. Gerotziafas. (2010) Newer anticoagulants in 2009. Journal of Thrombosis and Thrombolysis 29:1, 92-104
CrossRef157
Terese T. Horlocker, Denise J. Wedel, John C. Rowlingson, F. Kayser Enneking, Sandra L. Kopp, Honorio T. Benzon, David L. Brown, John A. Heit, Michael F. Mulroy, Richard W. Rosenquist, Michael Tryba, Chun-Su Yuan. (2010) Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy. Regional Anesthesia and Pain Medicine 35:1, 64-101
CrossRef158
A. Sautet. 2010. La prévention thrombo-embolique en chirurgie orthopédique et traumatologique majeure. , 269-278.
CrossRef159
Fred D. Cushner, Michael P. Nett. (2009) Unanswered Questions, Unmet Needs in Venous Thromboprophylaxis. Orthopedics 32:12/Supplement, 62-66
CrossRef160
A. GÃMEZ-OUTES, Ma. L. SUÃREZ-GEA, A. BLÃZQUEZ-PÃREZ, C. POZO-HERNÃNDEZ, E. VARGAS-CASTRILLÃN. (2009) Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?. Journal of Thrombosis and Haemostasis 7:12, 2149-2150
CrossRef161
Geoffrey H. Westrich, Lindsey J. Bornstein. (2009) Prophylactic Modalities: Pharmacologic and Mechanical Compression. Seminars in Arthroplasty 20:4, 235-240
CrossRef162
Luciana Armaganijan, John Eikelboom, Jeff S. Healey, Carlos A. Morillo. (2009) New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. Advances in Therapy 26:12, 1058-1071
CrossRef163
Richard J. Friedman. (2009) New Oral Anticoagulants for Thromboprophylaxis After Total Hip or Knee Arthroplasty. Orthopedics 32:12/Supplement, 79-84
CrossRef164
B. Heindl, M. Spannagl. (2009) Neue orale Antikoagulanzien. Der Anaesthesist 58:12, 1252-1255
CrossRef165
Davide Imberti, Chiara Dall’Asta, Matteo Giorgi Pierfranceschi. (2009) Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Internal and Emergency Medicine 4:6, 471-477
CrossRef166
R. Mahnel, S. Bassus, C.M. Kirchmaier. (2009) Blutungskomplikationen unter Antikoagulanzientherapie. Der Internist 50:12, 1369-1380
CrossRef167
Fred D. Cushner, Michael P. Nett. (2009) The Future of Thromboembolic Prophylaxis. Seminars in Arthroplasty 20:4, 251-254
CrossRef168
L. C. Borris. (2009) Barriers to the optimal use of anticoagulants after orthopaedic surgery. Archives of Orthopaedic and Trauma Surgery 129:11, 1441-1445
CrossRef169
Walter Ageno. (2009) Rivaroxaban for venous thromboembolism prevention after total knee arthroplasty: RECORD3 findings. European Journal of Orthopaedic Surgery & Traumatology 19:8, 529-533
CrossRef170
(2009) New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell. ANZ Journal of Surgery 79:11, 773-774
CrossRef171
Juan V Llau, Raquel Ferrandis. (2009) New anticoagulants and regional anesthesia. Current Opinion in Anaesthesiology 22:5, 661-666
CrossRef172
Laura McCullagh, Lesley Tilson, Cathal Walsh, Michael Barry. (2009) A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting. PharmacoEconomics 27:10, 829-846
CrossRef173
M. Houman Fekrazad, Renato D. Lopes, Gregg J. Stashenko, John H. Alexander, David Garcia. (2009) Treatment of venous thromboembolism: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 28:3, 270-275
CrossRef174
Juan Ignacio Arcelus, Marc Cairols, Xavier Granero, David Jiménez, Juan Vicente Llau, Manuel Monreal, Vicente Vicente. (2009) Nuevos anticoagulantes orales: una visión multidisciplinaria. Medicina Clínica 133:13, 508-512
CrossRef175
Sabine Eichinger. (2009) Eingriff-spezifische Thromboseprophylaxe beim Erwachsenen. Wiener Medizinische Wochenschrift 159:19-20, 475-480
CrossRef176
Joseph A Caprini. (2009) Intermittent pneumatic compression and pharmacologic thrombosis prophylaxis. Current Opinion in Pulmonary Medicine 15:5, 439-442
CrossRef177
Kylie Lepic, Mark A Crowther. (2009) A logical approach to surgical thromboprophylaxis. Current Opinion in Hematology 16:5, 397-401
CrossRef178
Giuseppe Camporese, Enrico Bernardi. (2009) Low-molecular-weight heparin for thromboprophylaxis. Current Opinion in Pulmonary Medicine 15:5, 443-454
CrossRef179
Christian Musselmann. (2009) Häufigkeit venöser Thromboembolien in der orthopädischen Rehabilitation nach Hüft- und Knietotalendoprothesenimplantation. Medizinische Klinik 104:9, 694-698
CrossRef180
Jennifer Carreiro Zikria, Jack Ansell. (2009) Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Current Opinion in Hematology 16:5, 347-356
CrossRef181
Sean T. Duggan, Lesley J. Scott, Greg L. Plosker. (2009) Rivaroxaban. Drugs 69:13, 1829-1851
CrossRef182
J.F. Schenk, B. Stephan, M. Kusma, J. Groß, H. Eichler. (2009) Orthopädische Patienten mit bzw. ohne Thrombophilie. Der Orthopäde 38:9, 835-842
CrossRef183
Lassen, Michael Rud, Raskob, Gary E., Gallus, Alexander, Pineo, Graham, Chen, Dalei, Portman, Ronald J., . (2009) Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement. New England Journal of Medicine 361:6, 594-604
Full Text184
Geno Merli, Alex C. Spyropoulos, Joseph A. Caprini. (2009) Use of Emerging Oral Anticoagulants in Clinical Practice. Annals of Surgery 250:2, 219-228
CrossRef185
Jan Steffel, Thomas F Lüscher. (2009) Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. Journal of Cardiovascular Medicine 10:8, 616-623
CrossRef186
Nina Chetty Raju, Simon Dimmitt, John W Eikelboom. (2009) Rivaroxaban versus enoxaparin after total knee arthroplasty. The Lancet 374:9691, 681
CrossRef187
P. C. WONG, E. J. CRAIN, C. A. WATSON, B. XIN. (2009) Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. Journal of Thrombosis and Haemostasis 7:8, 1313-1320
CrossRef188
REBECCA L C ADAMS, ROBERT J BIRD. (2009) Review article: Coagulation cascade and therapeutics update: Relevance to nephrology. Part 1: Overview of coagulation, thrombophilias and history of anticoagulants. Nephrology 14:5, 462-470
CrossRef189
P L Gross, J I Weitz. (2009) New Antithrombotic Drugs. Clinical Pharmacology & Therapeutics 86:2, 139-146
CrossRef190
Laura L. Turner, Martin Lovell, Paul Skipper, Caroline R. Shiach. (2009) Are the new oral anticoagulant agents easy to use? Report from an orthopaedic ward. British Journal of Haematology 146:4, 461-464
CrossRef191
Renato D. Lopes, Richard C. Becker, David Garcia, Elaine M. Hylek, Christopher B. Granger, Dayse M. Lourenço, Helena B. Nader, Francisco H. A. Maffei, Fernando H. Y. Cesena, José C. Nicolau, Ari Timmerman, Ana T. Rocha, Edison F. Paiva, Helio P. Guimaraes, Antonio C. Carvalho, Elbio A. D’Amico, Carlos A. Moreira-Filho, José M. Aldrighi, Antonio C. Lopes. (2009) Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23–25, 2008, Sao Paulo, Brazil. Journal of Thrombosis and Thrombolysis 28:1, 106-116
CrossRef192
Terry Chen, Sum Lam. (2009) Rivaroxaban. Cardiology in Review 17:4, 192-197
CrossRef193
JL Mega, E Braunwald, S Mohanavelu, P Burton, R Poulter, F Misselwitz, V Hricak, ES Barnathan, P Bordes, A Witkowski, V Markov, L Oppenheimer, CM Gibson. (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. The Lancet 374:9683, 29-38
CrossRef194
Sam Schulman. 2009. Anticoagulants for the Treatment ofVenous Thromboembolism. , 155-170.
CrossRef195
Walter Ageno. (2009) Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Expert Review of Cardiovascular Therapy 7:6, 569-576
CrossRef196
Alexander G. G. Turpie. 2009. Oral Direct Factor Xa Inhibitors. , 307-326.
CrossRef197
Raffaele De Caterina, Steen Dalby Kristensen, Giulia Renda. (2009) New anticoagulants for atrial fibrillation. Journal of Cardiovascular Medicine 10:6, 446-453
CrossRef198
Alexander GG Turpie, Michael R Lassen, Bruce L Davidson, Kenneth A Bauer, Michael Gent, Louis M Kwong, Fred D Cushner, Paul A Lotke, Scott D Berkowitz, Tiemo J Bandel, Alice Benson, Frank Misselwitz, William D Fisher. (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. The Lancet 373:9676, 1673-1680
CrossRef199
M. R. LASSEN. (2009) Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials. Journal of Thrombosis and Haemostasis 7:5, 889-891
CrossRef200
Sylvia Haas. (2009) Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme. European Journal of Haematology 82:5, 339-349
CrossRef201
Douglas Elwood, Caroline Koo. (2009) Intraspinal Hematoma Following Neuraxial Anesthesia and Low-Molecular-Weight Heparin in Two Patients: Risks and Benefits of Anticoagulation. PM&R 1:4, 389-396
CrossRef202
C. W. Khoo, K.-H. Tay, E. Shantsila, G. Y. H. Lip. (2009) Novel oral anticoagulants. International Journal of Clinical Practice 63:4, 630-641
CrossRef203
Beverley J. Hunt. (2009) The prevention of hospital-acquired venous thromboembolism in the United Kingdom. British Journal of Haematology 144:5, 642-652
CrossRef204
Paris J Abrams, Christopher R Emerson. (2009) Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor. Pharmacotherapy 29:2, 167-181
CrossRef205
T. Michael Farley, Daniel Lewis, Tracy E. Macaulay. (2009) In the Pipeline: New Oral Anticoagulants for the Prevention of Venous Thromboembolism. Orthopedics 32:1, 35-39
CrossRef206
David Garcia. (2009) Novel anticoagulants and the future of anticoagulation. Thrombosis Research 123, S50-S55
CrossRef207
Yoshimasa SHIMOTO, Satoshi KUNITADA. (2009) FXa inhibitors : Updates on clinical trial. Japanese Journal of Thrombosis and Hemostasis 20:5, 527-533
CrossRef208
C. Francès. (2008) Quoi de neuf en médecine interne. Annales de Dermatologie et de Vénéréologie 135, S335-S342
CrossRef209
Alex C. Spyropoulos. (2008) Brave new world: The current and future use of novel anticoagulants. Thrombosis Research 123, S29-S35
CrossRef210
(2008) Rivaroxaban for Thromboprophylaxis. New England Journal of Medicine 359:20, 2174-2176
Full Text211
Javier Granero Xiberta, José María Soler Minoves, Laura Garcia Nuño. (2008) Enfermedad tromboembólica en pacientes de cirugía ortopédica. Medicina Clínica 131, 18-24
CrossRef212
(2008) Rivaroxaban prevents blood clots after major orthopedic surgery. Nature Clinical Practice Rheumatology 4:10, 506-506
CrossRef213
RICARDO J. KOMOTAR, ROBERT M. STARKE, E. SANDER CONNOLLY. (2008) Orally Administered Factor Xa Inhibitor, Rivaroxaban. Neurosurgery 63:4, N10-N11
CrossRef214
Dagmar Kubitza, Michael Becka, Angelika Roth, Wolfgang Mueck. (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Current Medical Research and Opinion 24:10, 2757-2765
CrossRef215
H. R. Buller, A. W. A. Lensing, M. H. Prins, G. Agnelli, A. Cohen, A. S. Gallus, F. Misselwitz, G. Raskob, S. Schellong, A. Segers, . (2008) A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 112:6, 2242-2247
CrossRef216
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:9, 770-776
CrossRef217
Alexander G.G. Turpie. (2008) Warfarin replacements: Mechanisms underlying emerging agents. Canadian Journal of Cardiology 24, 56C-60C
CrossRef218
A Veiraiah, HGM Shetty, PA Routledge. (2008) Prevention and treatment of venous thromboembolism in older people. Reviews in Clinical Gerontology 18:03, 219
CrossRef219
Lohrmann, Jens, Becker, Richard C., . (2008) New Anticoagulants — The Path from Discovery to Clinical Practice. New England Journal of Medicine 358:26, 2827-2829
Full Text220
C. W. Francis. (2008) New Issues in Oral Anticoagulants. Hematology 2008:1, 259-265
CrossRef
- Letters
